← Back to patent-cliff list
SRP-100
Tier C — Watch / tradeSRP-100
Serpin Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LRP1
Indications (approved)：急性肾损伤, Myocardial infarction, Inflammatory disease, Peripheral nervous system disorder, Pneumonia, COVID-19
Regional status
US
Phase II
2020-02-24
EU
Phase II
2026-09-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SRP-100?
Approved indications include: 急性肾损伤, Myocardial infarction, Inflammatory disease, Peripheral nervous system disorder, Pneumonia, COVID-19.
When does the SRP-100 patent expire?
No public expiry year is available for SRP-100 yet; this page updates once verified.
How do I get a quote for SRP-100 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07